GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnGes Inc (OTCPK:AMGXF) » Definitions » EV-to-EBITDA

AnGes (AMGXF) EV-to-EBITDA : -3.28 (As of May. 28, 2025)


View and export this data going back to 2014. Start your Free Trial

What is AnGes EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AnGes's enterprise value is $137.50 Mil. AnGes's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-41.98 Mil. Therefore, AnGes's EV-to-EBITDA for today is -3.28.

The historical rank and industry rank for AnGes's EV-to-EBITDA or its related term are showing as below:

AMGXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -72.09   Med: -3.74   Max: -0.54
Current: -3.19

During the past 13 years, the highest EV-to-EBITDA of AnGes was -0.54. The lowest was -72.09. And the median was -3.74.

AMGXF's EV-to-EBITDA is ranked worse than
100% of 501 companies
in the Biotechnology industry
Industry Median: 8.16 vs AMGXF: -3.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-28), AnGes's stock price is $0.3602. AnGes's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.751. Therefore, AnGes's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


AnGes EV-to-EBITDA Historical Data

The historical data trend for AnGes's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnGes EV-to-EBITDA Chart

AnGes Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.83 -3.10 -0.89 -1.18 -2.40

AnGes Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 -0.81 -1.20 -2.40 -

Competitive Comparison of AnGes's EV-to-EBITDA

For the Biotechnology subindustry, AnGes's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnGes's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnGes's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AnGes's EV-to-EBITDA falls into.


;
;

AnGes EV-to-EBITDA Calculation

AnGes's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=137.497/-41.978
=-3.28

AnGes's current Enterprise Value is $137.50 Mil.
AnGes's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AnGes  (OTCPK:AMGXF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

AnGes's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3602/-0.751
=At Loss

AnGes's share price for today is $0.3602.
AnGes's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.751.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


AnGes EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AnGes's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AnGes Business Description

Traded in Other Exchanges
Address
7-7-15, Saito-asagi, 4F, Saito Bio-Incubator, Ibaraki, Osaka, JPN, 567-0085
AnGes Inc is a biopharmaceutical company. The company's development projects include - HGF plasmid, NFkB decoy oligonucleotide, and Therapeutic vaccine.

AnGes Headlines

No Headlines